Xeltis sets crosshairs on US pivotal trial for aXess after IDE green light

The US Food and Drug Administration (FDA) has granted an investigational device exemption (IDE) to Xeltis, green-lighting a pivotal study evaluating its haemodialysis vascular access device aXess.